Written by Scott Matusow, Mr.Matusow holds a position in the company featured in this article. Last week, Cubist Pharmaceuticals Inc. (CBST) agreed to buy Trius Therapeutics Inc. (TSRX) and Optimer Pharmaceuticals Inc. (OPTR) for as much as $1.62 billion. Cubist…
Bullish Free Articles
Biodel Expecting To Release Top-Line Data Soon
Biodel (BIOD) is expecting top-line Phase II data for BIOD-123 to be released in the third quarter 2013. With the market for these products estimated to be about $10 billion in value, good results for Biodel’s product would be a…
Significant Near Term Catalyst Should Further Rally Keryx Pharmaceuticals
Recently, we have detailed companies that have released positive Phase III data because we believe several of these companies continue to be under speculation value. Companies who have strong management, cash, and a strong pipeline can be very profitable for…
4 Biopharmas On Catalyst Watch List For Week 7/8/2013
Stockmatusow.com has compiled 4 biopharmas with significant near-term catalysts ahead that should drive their respective stock prices higher. We think each of these companies should also be looked at for speculation investments. Since the companies listed below are smaller caps,…
Cempra’s Platform Potentially Worth Billions In Battling Superbugs And MRSA
Written by StockMatusow.com writers Scott Matusow and Kyle Dennis. Mr.Matusow and Mr. Dennis hold positions in Cempra. During volatile market conditions, many investors decide to sell to protect profit. Investors have seen extraordinary gains so far in 2013 and stocks…
Biodel Primed To Capitalize On Next Generation Treatments In The $10B Diabetes Market
Glucose is one of the most important chemical structures because it is essential in providing the body with energy. It is integral in the chemical process called aerobic respiration, which generates a usable form of energy. Glycolysis is the beginning…
Wednesday’s Biotech Catalyst Trade Watch List
Today, I list four biotech companies with significant near-term catalysts ahead. Under normal market conditions, these stocks should see decent to very strong appreciation in the short-term. There are various ways to play these catalyst trades. Traders and investors can…
Trius Therapeutics: The Next Big Small-Cap Biotech Mover?
Normally, I write about biotech companies with near-term catalysts I feel offer traders good long based trade opportunities heading into these catalysts. Every so often, I find a small cap biotech where I feel a speculation investment is truly warranted.…
Video Chart Analysis and Commentary on Trius Therapeutics ($TSRX)
Video Chart analysis and commentary on Trius Therapeutics (TSRX). From the Aegis analyst report, we read the following: In the wake of this data, we are raising our probability of success for tedizolid from 60% to 80%, which increases the…
4 Top Small Cap Biotech Acquisition Targets
Today, I list small cap companies I believe are top acquisition targets for large pharma. I combine speculation, rumors and buzz I am hearing, and company financial position as a few factors for consideration. Buy-outs are hard to predict in…
